MUSTANG BIO INC (MBIO) Stock Price, Quote, News and Overview
NASDAQ:MBIO - Nasdaq - US62818Q2030 - Common Stock - Currency: USD
MBIO Quote, Performance and Key Statistics
MUSTANG BIO INC
NASDAQ:MBIO (2/4/2025, 8:00:00 PM)
After market: 3.79 +0.16 (+4.41%)3.63
-0.37 (-9.25%)
The current stock price of MBIO is 3.63 USD. In the past month the price decreased by -66.73%. In the past year, price decreased by -94.58%.
MBIO Latest News, Press Releases and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Top movers in Thursday's session
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Gapping stocks in Thursday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Wednesday's after hours session: top gainers and losers
After hours stock analysis on 2025-01-15: top gainers and losers in today's session.
MBIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About MBIO
Company Profile
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester Massachusetts, Massachusetts and currently employs 80 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. The company is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Company Info
MUSTANG BIO INC
377 Plantation Street
Worcester Massachusetts MASSACHUSETTS 01605 US
CEO: Manuel Litchman
Employees: 80
Company Website: https://www.mustangbio.com/
Investor Relations: https://ir.mustangbio.com/
Phone: 17816524500
MBIO FAQ
What is the stock price of MBIO?
The current stock price of MBIO is 3.63 USD.
What is the symbol for MUSTANG BIO INC stock?
The exchange symbol of MUSTANG BIO INC is MBIO and it is listed on the Nasdaq exchange.
On which exchange is MBIO stock listed?
MBIO stock is listed on the Nasdaq exchange.
Is MBIO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MBIO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MBIO.
Does MBIO stock pay dividends?
MBIO does not pay a dividend.
What is the Price/Earnings (PE) ratio of MBIO?
MBIO does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.32).
MBIO Technical Analysis
MBIO Financial Highlights
Over the last trailing twelve months MBIO reported a non-GAAP Earnings per Share(EPS) of -6.32. The EPS decreased by 43.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -325.54% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MBIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.